Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. Chief Financial Officer Lucera Erick reported an open-market sale of 2,362 shares of common stock at a weighted average price of $20.37 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the vesting and settlement of restricted stock units.
After this transaction, Erick beneficially owns 121,563 shares of Dyne Therapeutics common stock, which includes 110,513 unvested restricted stock units that continue to tie a substantial portion of compensation to the company’s future performance.
Dyne Therapeutics, Inc. director-affiliated investment funds reported open-market sales of a total of 267,760 shares of Common Stock over June 23–25, 2026. The trades were executed at weighted average prices around $21 per share, with reported ranges from $21.00 to $21.50.
According to the footnotes, the shares are held indirectly through Atlas Venture entities, including Atlas Venture Fund XI and Atlas Venture Opportunity Funds I and II, as well as AVA XI LP. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on March 19, 2026, and that Jason P. Rhodes disclaims Section 16 beneficial ownership in these funds beyond any pecuniary interest.
Dyne Therapeutics affiliate Erick Lucera filed a Form 144 proposing the sale of restricted and registered common stock. The filing lists a proposed sale of 5,727 shares with an execution date 04/01/2026 and 1,448 shares with an execution date 05/13/2026. The excerpt also shows 2,362 restricted stock units dated 05/12/2026 tied to equity compensation.